Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Helicobacter & Campylobacter May Play Roles in IBD

Reuters Staff  |  November 9, 2015

NEW YORK (Reuters Health)—Helicobacter and Campylobacter species appear to play opposing roles in inflammatory bowel disease (IBD), according to a systematic review and meta-analysis. The prevalence of IBD has increased steadily in the face of falling H. pylori infection rates, suggesting a negative association, whereas some studies have suggested that some Campylobacter species are involved…

Ro60 Autoantigen Regulates Inflammatory Gene Expression

Lara C. Pullen, PhD  |  November 9, 2015

New research links the RNA binding protein Ro60 with SLE pathogenesis and disease-causing inflammation…

High-Spending Doctors Are Less Likely to Be Sued

Andrew M. Seaman  |  November 5, 2015

NEW YORK (Reuters Health)—Providing more care than necessary may work to lower a doctor’s risk of being accused of malpractice, suggests a new U.S. study. Although the results can’t prove extra expenditures are due to defensive medicine, the researchers found that doctors in Florida who provided the most costly care between 2000 and 2009 were…

Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer

Will Boggs, MD  |  November 4, 2015

NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of…

German Registry Evaluates Systemic Psoriasis Treatments

Michele B. Kaufman, PharmD, BCGP  |  November 4, 2015

The German Psoriasis Registry, PsoBest, found conventional systemic and biologic drugs for psoriasis demonstrated relative safety from serious adverse events in patients between January 2008–December 2012…

RA Patients on DMARDs Have Higher Risk of Infection

Richard Quinn  |  November 3, 2015

Preventing infection in patients with RA should be a consideration for rheumatologists prescribing disease modifying anti-rheumatic drugs after a Swedish study found patients on these therapies have a 6.1% risk of developing serious infection.

Online Tool Helps RA Patients Make Informed Decisions

Arthritis Care & Research  |  November 3, 2015

Should you escalate care to a biologic? Many RA patients find this decision difficult and may need extra support and education to come to an informed decision. A recent study on this issue tested the value of a Web-based interactive decision support tool, which was developed with patient and physician input. After eight weeks, patients using the tool showed a measurable increase in the objective and subjective knowledge needed for making an informed decision compared with standard care…

Adverse Events More Common with Off-Label Drug Use

Will Boggs, MD  |  November 2, 2015

NEW YORK (Reuters Health)—Adverse drug events (ADEs) are more common when drugs are used off label, especially when the off-label use lacks strong scientific evidence, researchers from Canada report. “Our study demonstrated that physicians need to be cautious in prescribing off-label when there is a lack of strong scientific evidence for the use of the…

Genetic Data Suggest Dividing IBD into 3 Forms

Will Boggs, MD  |  November 2, 2015

NEW YORK (Reuters Health)—Data from a genetic association study suggest that inflammatory bowel disease (IBD) should be divided into a three-group continuum, rather than the current division between Crohn’s disease and ulcerative colitis. “The current clinical classifications of IBD, while important and useful, are a simplification of the true biological variation of this disease,” Dr….

CD64 May Be an RA-Specific Biomarker

Lara C. Pullen, PhD  |  November 2, 2015

A new study found patients with early RA had increased membrane and soluble CD64. After receiving anti-rheumatic therapy, patients’ symptoms and CD64 levels decreased, suggesting CD64 is an RA biomarker…

  • « Previous Page
  • 1
  • …
  • 549
  • 550
  • 551
  • 552
  • 553
  • …
  • 819
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences